| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ke Wu | |
| Cheng-Long Xie | |||
| Hui-Jun Chen | |||
| Jin-Cai He | |||
| Xing-Ru Zhang | |||
| Zeng-Rui Zhang | |||
| Zhi-Yu Jiang | |||
| P2860 | cites work | Movement Disorders | Q1486418 |
| The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease | Q52016073 | ||
| Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease | Q53839390 | ||
| Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan | Q56441169 | ||
| Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results | Q57083753 | ||
| Levodopa-induced dyskinesia in Parkinson disease: Current and Evolving Concepts | Q57789579 | ||
| Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease | Q27325443 | ||
| The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations | Q28180426 | ||
| Systematic evaluation of rating scales for impairment and disability in Parkinson's disease | Q28205111 | ||
| Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study | Q30366253 | ||
| Meta-analysis of data from animal studies: a practical guide | Q30671623 | ||
| Pooling of animal experimental data reveals influence of study design and publication bias | Q30918723 | ||
| Problems related to levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease | Q33917419 | ||
| Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets | Q34209542 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease | Q34554465 | ||
| Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results | Q36361513 | ||
| Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease | Q36641474 | ||
| Interpretation of tests of heterogeneity and bias in meta-analysis | Q37329334 | ||
| Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients | Q37344109 | ||
| Oral and infusion levodopa-based strategies for managing motor complications in patients with Parkinson's disease | Q37678381 | ||
| Movement disorders in 2010: Parkinson disease-symptoms and treatments | Q37836371 | ||
| Late-stage Parkinson disease. | Q38024984 | ||
| Levodopa therapy for Parkinson disease: A look backward and forward | Q38798109 | ||
| Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets | Q44463177 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 845-854 | |
| P577 | publication date | 2020-02-26 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review | |
| P478 | volume | 14 |
Search more.